Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.87 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.87 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.87 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.87 |
| ▸ | MAPT | P10636 | 1/20 | 0.87 |
| ▸ | STAT3 | P40763 | 1/20 | 0.87 |
| ▸ | CLK1 | P49759 | 1/20 | 0.71 |
| ▸ | CCR5 | P51681 | 1/20 | 0.69 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | IDE | P14735 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9977996 | 0.93 | MEN1 (0.83) | MEN1KMT2ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL9978124 | 0.93 | MEN1 (1.00) | MEN1KMT2ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL19410590 | 0.92 | MEN1 (0.74) | MEN1KMT2ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL19422869 | 0.92 | MEN1 (0.81) | MEN1KMT2ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL9978123 | 0.89 | MEN1 (0.87) | MEN1KMT2ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL19422870 | 0.89 | MEN1 (0.87) | MEN1KMT2ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL9978126 | 0.88 | MEN1 (0.74) | MEN1KMT2ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL9978122 | 0.86 | SMN1; SMN2 (0.72) | MEN1KMT2ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL30061909 | 0.86 | MAPK1 (0.75) | MEN1KMT2ASMN1; SMN2MAPK1MAPT | |
| SCHEMBL17540869 | 0.84 | MEN1 (0.76) | MEN1KMT2ASMN1; SMN2MAPK1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170281611-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | EIGER BIOPHARMACEUTICALS, INC. (US) | 2017-10-05 | — | — | US | disclosed |
| WO-2016032569-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | CELLADON CORPORATION (US) | 2016-03-03 | — | — | WO | disclosed |
| WO-2016032569-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | CELLADON CORPORATION (US) | 2016-03-03 | — | — | WO | disclosed |
| US-9221840-B2 | Treating protein folding disorders with small molecule CFTR correctors | DISCOVERYBIOMED INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-9221840-B2 | Treating protein folding disorders with small molecule CFTR correctors | DISCOVERYBIOMED INC. (US) | 2015-12-29 | — | — | US | disclosed |
| US-20140073632-A1 | TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS | THE UAB RESEARCH FOUNDATION (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140073632-A1 | TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS | THE UAB RESEARCH FOUNDATION (US) | 2014-03-13 | — | — | US | disclosed |
| WO-2012158913-A2 | TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS | DISCOVERYBIOMED INC. (US) | 2012-11-22 | — | — | WO | disclosed |
| WO-2012079164-A1 | ACTIVATORS OF CYLINDRICAL PROTEASES | THE GOVERNING COUNCIL OF THE UNIVERSITY OF TORONTO (CA) | 2012-06-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170281611-A1 | QUINOLINES AND THEIR USE FOR TREATING ENDOPLASMIC RETICULUM STRESS-CAUSED DISEASES | ATP2A1, ATP2A3, ATP2A2 | MEN1 4199/4885KMT2A 4359/4885SMN1; SMN2 698/4885 |
| US-20140073632-A1 | TREATING PROTEIN FOLDING DISORDERS WITH SMALL MOLECULE CFTR CORRECTORS | CFTR, CLCN2, SLC47A1 | MEN1 4193/4885KMT2A 4502/4885SMN1; SMN2 1902/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.